Omnicell, Inc.

  • Market Cap: Small Cap
  • Industry: Computers - Software & Consulting
  • ISIN: US68213N1090
USD
39.61
1.15 (2.99%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Omnicell, Inc. stock-summary
stock-summary
Omnicell, Inc.
Computers - Software & Consulting
Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.
Company Coordinates stock-summary
Company Details
590 E Middlefield Rd , MOUNTAIN VIEW CA : 94043-4008
stock-summary
Tel: 1 650 2516100
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 103 Schemes (65.86%)

Foreign Institutions

Held by 143 Foreign Institutions (17.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Randall Lipps
Chairman of the Board, President, Chief Executive Officer
Mr. James Judson
Lead Independent Director
Mr. Robin Seim
Director
Ms. Joanne Bauer
Independent Director
Mr. Vance Moore
Independent Director
Mr. Mark Parrish
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
291 Million
(Quarterly Results - Jun 2025)
Net Profit:
6 Million
stock-summary
Industry

Computers - Software & Consulting

stock-summary
Market cap

USD 1,805 Million (Small Cap)

stock-summary
P/E

78.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.06

stock-summary
Return on Equity

1.94%

stock-summary
Price to Book

1.43